Traders should monitor for follow-up trial updates, potential trial expansion or fast-track designation, and any signs of partnership interest, as these data may position darlifarnib as a meaningful combination therapy in refractory RCC. The stock may react positively to further de-risking of the program.
KURA drugs
KURA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 17 $9.68entry
- T+1 · 7mo ago +1.03%α +1.22% · $9.78
- T+5 · 7mo ago −4.34%α −4.89% · $9.26
- T+20 · 6mo ago +0.62%α −4.75% · $9.74
- T+60 · 4mo ago +16.12%α +9.97% · $11.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology announced preliminary clinical data from a subset of patients with clear cell renal cell carcinoma (ccRCC) previously treated with cabozantinib, showing a 44% objective response rate and 94% disease control rate with its investigational combination of darlifarnib and cabozantinib. The results suggest potential to overcome resistance to VEGF TKI therapy in a heavily pretreated population, with durable responses observed and a manageable safety profile. The data were presented at IKCS: Europe and discussed in a virtual investor event.
Key Facts
- Preliminary data from 16 ccRCC patients previously treated with cabozantinib showed a 44% objective response rate (ORR) and 94% disease control rate (DCR).
- Tumor shrinkage occurred in 75% of patients, with reductions ranging from 32% to 47% among responders.
- Treatment durations ranged up to 56 weeks, with one-third of patients still on therapy at data cutoff.
- Darlifarnib is being evaluated in combination with cabozantinib in the ongoing FIT-001 trial, with dose expansion underway.
- Virtual investor event held on April 17, 2026, to discuss findings.
Financial Impact
No direct financial figures disclosed, but strong clinical data may enhance valuation and partnership potential.
Risk Factors
- Data are preliminary and from a small subset (n=16), with limited statistical power.
- Future clinical trials may not replicate these results, and regulatory approval is not guaranteed.
- Competition in the RCC space is intense, with multiple existing and emerging therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276007 |
Track record
29 reports on KURA
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers